Last reviewed · How we verify
Neutrogena Rapid Clear®
Neutrogena Rapid Clear® contains benzoyl peroxide, which kills acne-causing bacteria and reduces sebum production on the skin.
Neutrogena Rapid Clear contains benzoyl peroxide, which kills acne-causing bacteria and reduces sebum production on the skin. Used for Acne vulgaris (mild to moderate).
At a glance
| Generic name | Neutrogena Rapid Clear® |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Topical antimicrobial/keratolytic agent |
| Target | Cutibacterium acnes (bacterial cell membranes and proteins) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Benzoyl peroxide is a topical antimicrobial and keratolytic agent that penetrates the skin to eliminate Cutibacterium acnes (formerly Propionibacterium acnes) bacteria in follicles and sebaceous glands. It also promotes desquamation and reduces comedone formation by normalizing skin cell turnover. The mechanism is bactericidal rather than bacteriostatic, making resistance development unlikely.
Approved indications
- Acne vulgaris (mild to moderate)
Common side effects
- Skin irritation/erythema
- Dryness
- Peeling
- Contact dermatitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neutrogena Rapid Clear® CI brief — competitive landscape report
- Neutrogena Rapid Clear® updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI